Diet for Hypoglycemia - Hypoglycemia Diet News

Hypoglycemia Diet News

Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added To Lantus(R) Saturday, July 10, 2010 @ 6:28AMAmylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTA® (exenatide) injection added to Lantus® (insulin glargine), which showed patients with type 2 diabetes achieved glucose targets without weight gain or increasing their risk of hypoglycemia. These findings were ...
Tour de France Stage 4: Get over it to get to the Alps Friday, July 9, 2010 @ 4:37PMGet over it is often tough-love advice to a person whining about something perceived as petty.
On Nutrition: Conversation about diabetes Tuesday, July 6, 2010 @ 9:07PMControlling type 1 diabetes like "fencing in the fog"
Hope for people with type 2 diabetes Tuesday, June 1, 2010 @ 3:43PMRick Gallop published his first book on the G.I. diet (Glycemic Index Diet) in 2002. He followed that one up with several others, but his most recent book makes a big claim. It's called The G.I. Diet Diabetes Clinic: A Week-by-Week Guide to Reversing Diabetes (Random House, $24.95).
The Lancet Publishes New Data Demonstrating Superior Efficacy Of Victoza(R) (liraglutide [rDNA] Injection) Compared To ... Saturday, April 24, 2010 @ 6:44AMYesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza® (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia®. The 26-week trial showed that Victoza® produced significantly greater reductions in A1C, fasting plasma glucose (FPG), and body weight than Januvia®, with similar or better overall treatment satisfaction...
AFREZZA Inhalation Powder reduces incidence of hypoglycemia in patients with Type 1 diabetes Saturday, April 24, 2010 @ 3:51AMDiabetes treatment regimens containing AFREZZATM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, provide glucose control similar to standard insulin therapy along with weight loss and reduced incidence of hypoglycemia in patients with Type 1 diabetes and poorly controlled blood sugar levels, according to a two-year study presented today at the ...
The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to ... Friday, April 23, 2010 @ 11:10AMPRINCETON, N.J., April 23 /PRNewswire-FirstCall/ -- Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza® (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia®.
New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With ... Friday, April 23, 2010 @ 8:45AMResults of a new study showed that WelcholÂ® 3.75 g/d significantly improved lipid and glycemic measures in patients with high LDL cholesterol and prediabetes . Â The randomized, placebo-controlled, double-blind study was presented today at the American Association of Clinical Endocrinologists 19th Annual Meeting and Clinical Congress in Boston. Â These data are consistent with previous studies ...
The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to ... Friday, April 23, 2010 @ 7:14AMPRINCETON, NJ--(Marketwire - April 23, 2010) - Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza ® (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia ® . The 26-week trial showed that Victoza ® produced significantly greater reductions in A1C, fasting plasma glucose (FPG), and body weight than Januvia ® , with ...
The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA ] injection) compared ... Friday, April 23, 2010 @ 7:00AMPRINCETON, NJ--(Marketwire - 04/23/10) - Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA ] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose (FPG), and body weight than Januvia, with similar or ...
The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA ] injection) compared ... Friday, April 23, 2010 @ 7:00AMYesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, VictozaÂ® with a DPP-4 inhibitor, JanuviaÂ®. Â The 26-week trial showed that VictozaÂ® produced significantly greater reductions in A1C, fasting plasma glucose , and body weight than JanuviaÂ®, with similar or better overall treatment satisfaction.
Press Release Friday, April 23, 2010 @ 4:39AMAlkermes Inc. Posted on:23 Apr 10 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for ...
Christiane Northrup, MD: The Magic of Magnesium: A Mighty Mineral Essential to Health Tuesday, March 30, 2010 @ 8:25AMWhen it comes to building healthy bones, magnesium is as important as calcium and vitamin D are! Without adequate magnesium too much calcium gets inside the cell, causing unforeseen complications.
Switching to Once-Daily Victoza(R) (Liraglutide [rDNA Origin ] Injection) from Exenatide Further Improves Blood Sugar ... Tuesday, March 30, 2010 @ 7:00AMDiabetes Care published online the results of the Novo Nordisk LEADâ¢ 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily VictozaÂ®. Â Results show that when added to oral antidiabetes drugs , patients who switched from exenatide to Victoza experienced further reductions in A1c and weight loss.
Ask Dr. Gott: Drugs linked to dyskinesia Friday, January 29, 2010 @ 3:39AMDear Dr. Gott: Do you have any information on tardive dyskinesia? My husband has it, and there seems to be little known about it.
Neuroleptic drugs linked to tardive dyskinesia Thursday, January 28, 2010 @ 11:02PMDEAR DR. GOTT: Do you have any information on tardivedyskinesia? My husband has it, and there seems to be little knownabout it.
Visiting Veterinarian : Picky eaters Wednesday, December 30, 2009 @ 6:42PMBy Michelle Gerhard Jasny V.M.D. Published: December 31, 2009 If your family is like mine, over the holidays all pretense of healthy eating has gone out the window.
Mind Matters: Try these stress-fighting techniques Thursday, October 15, 2009 @ 7:14PMThere are many measures that may alleviate or treat anxiety, a pervasive problem of society today. Prevention is the first step. Some individuals are more prone to anxiety than others. This is due in part to heredity, as well as personality type and effects of child rearing.
Mind Matters: Try these stress-fighting techniques Thursday, October 15, 2009 @ 7:05PMThere are many measures that may alleviate or treat anxiety, a pervasive problem of society today. Prevention is the first step. Some individuals are more prone to anxiety than others. This is due in part to heredity, as well as personality type and effects of child rearing. Individuals may have exposed in childhood to harsh disciplinary practices or abuse, which predispose some to a tendency ...
Merck Receives Positive CHMP Opinion For JANUVIA (Sitagliptin) And JANUMET (Sitagliptin/Metformin) As Add-On To ... Tuesday, September 29, 2009 @ 4:54AMMerck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA tablets and JANUMET tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.
Safety profiles of JANUVIA and JANUMET drugs established through clinical development program Monday, September 28, 2009 @ 5:31AMMerck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.
In Investigational Studies, New Uses of JANUVIA (sitagliptin) in Combination with Other Diabetes Medicines Resulted in ... Saturday, June 6, 2009 @ 10:12AMIn two new investigational studies evaluating the efficacy and tolerability of Merck & Co., Inc. (MRK, NYSE)'s diabetes medicine JANUVIA, JANUVIA significantly improved blood sugar control.
05-28-09 EUR ALL ON ONE PAGE Thursday, May 28, 2009 @ 2:19AMCHRIS BROWN SAYS 'I AIN'T A MONSTER': Singer records YouTube message; plus, both Brown and Rihanna have booked new movies. *Chris Brown has made his first public comments about the alleged beating he handed then-girlfriend Rihanna on Feb. 8, which led to his arrest and two felony assault charges.
Search the Archives Wednesday, May 27, 2009 @ 11:34PMSo you're past the point of "talking the talk," and you're ready to make bigger strides.